


ILLUSTRATION OF CSF COLLECTION



SHIPMENT OF CEREBROSPINAL FLUID SAMPLES

- **If the laboratory is located within your center:**
Bring the CSF sample immediately to the laboratory (in the PP tube, at room temperature).
- **If the laboratory is located outside your center with sample pretreatment on site:**
Bring the CSF sample immediately to the laboratory (in the PP tube, at room temperature). The local laboratory deals with centrifugation, decantation and shipping within 24 hours at room temperature, or freezing of the sample in case of delayed shipment.
- **If the laboratory is located outside your center without sample pretreatment on site:**
Send the CSF sample to the laboratory in charge of the assay within 4h after the LP (in the PP tube, at room temperature). The sampling and shipment hours should be reported for traceability.

Dr. Claire PAQUET is a neurologist, neuroscientist and neuropathologist at the expert memory center of Lariboisière Hospital in Paris, France (head of the department Prof. J. Hugon - www.parisnord.org)

Acknowledgements: Dr. Paquet, author and responsible editor of this leaflet wishes to thank Fujirebio Europe (ex-Innogenetics) for their sponsoring. Fujirebio Europe paved the way for Alzheimer's disease biomarkers. Fujirebio is a leading international healthcare company specialised in high quality IVD testing solutions.

Practical guide for lumbar puncture

Biomarkers for Alzheimer's disease in cerebrospinal fluid

Claire Paquet

BIBLIOGRAPHY

- van Veen et al., Br J Haematol. 2010 Jan;148(1):15-25.
- Wright et al., J Neurol. 2012 Aug;259(8):1530-45.
- Layton et al., Am J Neuroradiol. 2006 Mar;27(3):468-70.
- Shi et al., Neurology 2007 Sep; 69:1063-5.
- Ruff & Dougherty, Stroke 1981 Nov-Dec;12(6):879-81.
- Headache Classification Subcommittee of the International Headache Cephalalgia, 2004; 24, Suppl:9-160.
- Bateman et al., Neurology 2007 Feb;68:666-9.
- Bezov et al., Headache. 2010 Oct;50(9):1482-98.
- Turnbull et al., Br J Anaesth. 2003 Nov;91(5):718-29.
- Ahmed et al., Postgrad Med J. 2006 Nov;82(973):713-6.
- Kuczkowski, Am J Emerg Med. 2006 Oct;24(6):757.
- Clark et al., J Neurol Neurosurg Psychiatry. 1996 Jun;60(6):681-3.
- Follens et al., Bull Soc Belge Ophtalmol. 2001;(281):29-33.
- Leibold et al., Ann Emerg Med. 1993 Dec;22(12):1863-70.
- Cohen et al., Rev Med Interne. 1991 Nov-Dec;12(6):429-32.
- Zetterberg et al., Eur Neurol. 2010;63(6):326-30.
- van Oosterhout et al., Neurology. 2013 Mar;80(10):941-8.
- Wolcott et al., J Pediatr. 1970 Dec;77(6):1060-2.
- Lerner et al., Anesthesiology. 1973 Nov;39(5):550-1.
- Edelson et al., Arch Neurol. 1974 Aug;31(2):134-7.
- Messer et al., JAMA. 1976 Feb 2;235(5):529-30.
- Hurt et al., Surg Neurol. 1977 Oct ;8(4):296-7.
- Sadjadpour, JAMA. 1977 Apr 18;237(16):1692-3.
- Diaz et al., Neurosurgery. 1978 Nov-Dec;3(3):404-6.
- Laglia et al., Ann Intern Med. 1978 Apr;88(4):515-6.
- Dunn et al., JAMA. 1979 Apr 20;241(16):1712-3.
- Guthikonda et al., Neurosurgery. 1979 Nov;5(5):614-6.
- Brem et al., N Engl J Med. 1981 Apr 23;304(17):1020-1.
- Mayumi & Dohi, Anesth Analg. 1983 Aug;62(8):777-9.
- Owens et al., Anesth Analg. 1986 Nov; 65(11):1201-7.
- Spanu et al., Neurochirurgia (Stuttg). 1988 Sep;31(5):157-9.
- Scott et al., Neurosurgery. 1989 Aug;25(2):287-92.
- Vos et al., Clin Neurol Neurosurg. 1991;93(2):127-32.
- Peltola et al., Lancet. 1996 Jan 13;347(8994):131.
- Egede et al., Md Med J. 1999 Jan-Feb;48(1):15-7.
- Adler et al., Pediatr Emerg Care. 2001 Jun;17(3):184-8.
- Pai et al., Neurol India. 2002 Sep;50(3):367-9.
- Teksam et al., Neuroradiology. 2003 Aug;45(8):553-6.
- Paal et al., Anesth Analg. 2006 Feb;102(2):644-5.
- Kasliwal et al., Pan Arab J Neurosurg. 2010 Oct;14(2):96-8.
- Pavlin et al., Anesthesiology. 1979 Oct;51(4):338-40.
- Edelman et al., Anesthesiology. 1980 Feb;52(2):166-7.
- Kiersz et al., Lakartidningen. 1985 Aug 21;82(34):2795.
- Lam-My et al., Presse Med. 1987 Nov 21;16(39):1979-80.
- Lavie et al., Rev Neurol (Paris). 1998 Oct;154(10):703-5.
- Peiró et al., Rev Esp Anestesiol Reanim. 2003 Nov;50(9):481-5.
- Martin-Millán et al., Eur Neurol. 2005;53(3):159-60.
- Trunet et al., Neurochirurgie. 2008 Apr;54(2):85-8.
- Lee et al., Am J Med Sci. 2009 Feb;337(2):143-5.
- Zeidan et al., Middle East J Anesthesiol. 2010 Feb;20(4):483-92.
- Messori et al., Neurol Sci. 2001 Oct;22(5):411-2.
- Francia et al., Neurol Sci. 2001 Oct;22(5):385-9.
- Flora et al., Chest. 1990 Oct;98(4):1041.
- Kozikowski & Cohen, Anesth Analg. 2004 Feb;98(2):524-6.
- Flaatten et al., Acta Neurol Scand. 1998 Dec;98(6):445-51.
- Peskind et al., Curr Alzheimer Res. 2009 Jun;6(3):290-2.
- Flaatten et al., Acta Anaesthesiol Scand. 1998 Nov;42(10):1209-14.
- Richman et al., Neurologist. 2006 Jul;12(4):224-8.
- Evans et al., Neurology. 2000 Oct 10;55(7):909-14.
- Greene, JAMA. 1926;86(6):391-392.
- Jarvis et al., Anesth Analg. 1986 Mar;65(3):316-7.
- Yücel et al., Reg Anesth Pain Med. 1999 Jan-Feb;24(1):51-4.
- Kuntz et al., Neurology. 1992 Oct;42(10):1884-7.
- Lin & Geiderman, West J Med. 2002 Jan;176(1):69-70.
- McKhann et al., Alzheimers Dement. 2011 May;7(3):263-9.
- Sperling et al., Alzheimers Dement. 2011 May;7(3):270-9.
- Jack et al., Lancet Neurol. 2013 Feb;12(2):207-16.

DISCLAIMER: This Practice Guide was published under the responsibility of Dr. Claire Paquet. Fujirebio Europe shall in no event be liable for damages caused to patients in the process of performing a lumbar puncture. The physician performing the lumbar puncture is exclusively liable for this medical intervention.

© Dr. Claire Paquet 2015

BEFORE SUGGESTING A LUMBAR PUNCTURE...

- **Evaluate the rachis accessibility:**
In case of difficult access (when the intervertebral space is not palpable): consider for lumbar puncture (LP) under scopy.
- **Look for contraindications:**
 - Clotting problems (according to literature: thrombopenia $<60000^1$, thrombopenia 60000 with an increased bleeding time, PT, INR >1.5) and/or PTT abnormalities² or anticoagulant treatment.
 - Rachidian plaque, behavioural disorder.
 - Significantly increased intracranial pressure or any intracranial mass effect on imaging.
 - Skin infections or developmental anomalies (myelomeningocele) at the entrance site of the needle.

TO DO A LUMBAR PUNCTURE

- **Check haemostasis and brain imaging.**
- **Treatment with low molecular weight heparin should be stopped before LP²⁻³:**
 - 12h in case of prophylactic dose
 - 24h in case of hypocoagulant dose
- **Do the LP collection in the morning*.**
- **Use local anesthesia** (e.g. 1% lidocaine) or EMLA™ patch (at least 1h before LP). If necessary, give analgesic/sedative gas (e.g. Kalinox®) and/or low dose of anxiolytic drugs.
- **All the necessary material must be ready on a trolley:** trash can, sterile gloves and mask, antiseptic solution, physiological salt solution, sterile compresses, dressing, dedicated needle for LP, polypropylene (PP) tubes indicated by your laboratory and tubes for biochemistry, bacteriology, cytology.
- **Position of the patient:** sitting or lying down in lateral recumbent position, with rachis parallel to the bed. In this position, look for the L4L5 lumbar space (centre of line joining the two posterior iliac crests) or the L3L4 lumbar space above.
- **Disinfect the skin around the entrance site of the needle according to your standard procedure.**
- **Lumbar puncture procedure:** Do not touch the metal part of the needle. Orient the bevel parallel to the longitudinal dural fibers. Insert the needle forwards, with a slight angle upwards. Advance slowly but smoothly. A resistance change is felt when inserting the needle through the yellow ligament, with a characteristic "pop" when the needle penetrates the dura. The stylet should be withdrawn and observed for fluid return.
- **If heparinotherapy is necessary, post-LP introduction should be delayed at least 1h to minimize the risk of hematoma¹³³⁻⁵.**
- **For cerebrospinal fluid (CSF) biomarkers (Alzheimer-specific proteins):**
 - do not use the 20 first drops
 - collect CSF (≥ 4 ml) directly in the PP tube
- **At the end of CSF sampling, replace the stylet and remove the needle.** Clean the skin and apply a sterile dressing.
- **Place the patient in a supine position.** The patient should refrain from any physical activity for 24 hours or long travels.
- **Prescribe simple analgesics, if needed.**

SIDE EFFECTS OF A LUMBAR PUNCTURE

- **Post-LP syndrome:**
the most frequent side effect, characterized by the appearance of an orthostatic headache is relieved by decubitus⁶. The intensity varies from mild to moderate. The headache can be frontal or occipital with irradiations to the neck and shoulders⁶⁻⁸. Post-LP syndrome can be accompanied by lumbar pain, dizziness, nausea, light and sound phobia, and exceptionally, paralysis of the brain nerves⁹⁻¹³. In 90% of cases, side effects will appear within 72h after the LP¹⁴⁻¹⁵.
Risk factors for post-LP syndrome include:
 - the patient's age: 10 to 15% in young patients, $<5\%$ in patients ≥ 65 years old, 2% in case of dementia¹⁶
 - low BMI¹⁷
- **Epidural or spinal subdural hematoma:**
of the 49 cases reported, 46% had thrombocytopenia, 36% had heparin treatment before or after the LP, 75% occurred after difficult or traumatic LP. To be evoked if there is a lumbar pain with paresthasias and/or paraparesis (therapeutic emergency)¹⁸⁻⁴⁰.
- **Intracranial subdural hematoma:**
8 cases described. To investigate if the post-LP syndrome lasts for more than 8 days or in case of loss of postural character of headache or appearance of localization signs³³⁻⁴⁴⁻⁵⁰.
- **Intracranial hypotension post-LP⁵¹⁻⁵².**
- **Dural abscess, pneumocephalus⁵³⁻⁵⁴, meningitis³⁶⁻³⁷.**

TO PREVENT SIDE EFFECTS

- Use an atraumatic needle or a narrow beveled needle (black/22gauge)^{8:55-56} introduction of the needle with upward inclination, minimizing the opening in the dura by squeezing the needle between dural fibers and repositioning of the stylet at the end of the LP⁵⁷⁻⁶⁰.
- Some studies have shown the benefit of a pretreatment with IV caffeine^{8:61-62}.

NOTE

- Collected volume of CSF (if <30 ml), number of attempts, patient position, duration of rest following LP, patient hydration, did not show any influence on the occurrence of a post-LP syndrome^{59-60,63-64}.
- There is neither consensus nor a risk-benefit study on performing the LP under anti-aggregant therapy.
- Migraine is not a related risk of CSF collection⁷.
- In case of a severe post-LP syndrome, treatment with a blood-patch is effective.



LINK WITH ALZHEIMER'S DISEASE

- The concentration of specific biomarkers in CSF (amyloid peptide, total and phosphorylated tau protein) reflects a biochemical change due to brain damage characteristic for Alzheimer's disease.
- Using these CSF biomarkers, Alzheimer's disease can be diagnosed accurately and early⁶⁵⁻⁶⁷.
- There may be a time lag between obvious pathophysiology and its symptomatic expression, making alterations in biomarker concentrations one of the first signs of Alzheimer's disease.

